A memorable day for Biogen investors

Biotech company Biogen’s promising treatment for the most common cause of dementia has just cleared a key hurdle.

912_MW_P29_Companies

Damaging amyloid plaques (in yellow) shrank when BAN2401 was taken
(Image credit: This content is subject to copyright.)

Biogen's promising treatment for the most common cause of dementia has just cleared a key hurdle.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Swipe to scroll horizontally
Biogen (Nasdaq: BIIB)
Investment measureInvestmentratio
Share price$354P/E 2018/2019*13
Market cap$71.2bnPEG1.5
Net debt (30/6/18)$1.5bn**Dividend yieldn/a
Recent results20172016% change
Turnover*$12.2bn$10.6bn15%
GAAP EPS$11.92$16.93-29.6%
Non-GAAP EPS$21.81$20.22+7.9%
DPSn/an/an/a
* Excluding sales now in Bioverativ
From MarketWatch data
** After share buybacks of $2.75bn in Q2
Dr Mike Tubbs

Highly qualified (BSc PhD CPhys FInstP MIoD) expert in R&D management, business improvement and investment analysis, Dr Mike Tubbs worked for decades on the 'inside' of corporate giants such as Xerox, Battelle and Lucas. Working in the research and development departments, he learnt what became the key to his investing; knowledge which gave him a unique perspective on the stock markets.

Dr Tubbs went on to create the R&D Scorecard which was presented annually to the Department of Trade & Industry and the European Commission. It was a guide for European businesses on how to improve prospects using correctly applied research and development. He has been a contributor to MoneyWeek for many years, with a particular focus on R&D-driven growth companies.